Form 4: Mirum Pharmaceuticals Director Equity Grant
Statement of Changes in Beneficial Ownership
Director Timothy P. Walbert received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.
Summary
- Director Timothy P. Walbert was granted 3,772 stock options with an exercise price of $101.
- Director Timothy P. Walbert was granted 1,980 restricted stock units (RSUs).
- Both the stock options and RSUs vest on the first anniversary of the grant date, or upon the 2027 annual stockholder meeting, whichever occurs first.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The issuance of new equity awards results in minor dilution to existing shareholders.
Risks
- Market volatility affecting the value of the granted equity.
- Potential for future share price fluctuations impacting the exercise value of the options.
Future Outlook
The equity grants are subject to standard vesting schedules tied to the 2027 annual stockholder meeting, indicating a commitment to board retention through the next fiscal year.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to ensure alignment with long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of a mix of stock options and RSUs is consistent with compensation structures at mid-cap biopharmaceutical companies.
- Vesting schedules tied to annual meetings are a common governance practice to ensure director continuity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Timothy P. Walbert appointed Doug Sheehy, Jody Howe, and Judit Ryvkin as attorneys-in-fact for SEC filings. | 06/10/2026 | Standard administrative procedure to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on the first anniversary of the grant or the 2027 annual stockholder meeting.
Key Dates
| Date | Description |
|---|---|
| 06/10/2026 | Date of Power of Attorney execution. |
| 06/15/2026 | Date of equity grant transaction. |
| 06/17/2026 | Date of filing. |
Keywords
Mirum Pharmaceuticals, MIRM, Director Compensation, Equity Grant, Stock Options, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.